ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth. Our clinically superior ADAPT® products are the only ones to have achieved over ten years without calcification or degradation. With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life. All Admedus ADAPT® products are manufactured in our state-of-the-art biomanufacturing facility which has substantial capacity to expand and includes an in-house research and development laboratory.
 Neethling, et al. Performance of the ADAPT® treated BioScaffold in paediatric patients with congenital cardiac anomalies: Medium to Long-Term Outcomes. Presented at the Joint European Congenital Heart Surgeons Society and World Society for Pediatric and Congenital Heart Surgery Congress. 20-22 June 2019. Sofia, Bulgaria.
 Bell D, Betts K, Justo R, Forde N, Venugopal P, Corno AF, Smith P, Caputo M, Marsico R, Karl TR, Alphonso N. Multi-centre experience with 500 CardioCel® implants used for the repair of congenital heart defects, The Annals of Thoracic Surgery (2019), doi: https://doi.org/10.1016/j.athoracsur.2019.04.085.
 Prabu S, Armes JE, Bell D, Justo R, Venuqopal P, Karl T, Alphonso N. Histologic Evaluation of Explanted Tissue-Engineered Bovine Pericardium (CardioCel). Semin Thorac Cardiovasc Surg. 2017 Autumn;29(3):356-363